Korean J Psychopharmacol.
2012 Jul;23(3):88-96.
An Open Label Multi-Center Prospective Observational Study of Paliperidone Extended Release to Assess the Medication Satisfaction and Treatment Response in Patients with Schizophrenia
- Affiliations
-
- 1Department of Psychiatry, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea. npkyh@chol.com
- 2Department of Psychiatry, Hongseong Medical Center, Hongseong, Korea.
- 3Department of Psychiatry, St. John of God Hospital, Gwangju, Korea.
- 4Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 5Department of Psychiatry, Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, Korea.
- 6Department of Psychiatry, Seodaegu Daedong Hospital, Daegu, Korea.
- 7Department of Psychiatry, Daedong Hospital, Daegu, Korea.
- 8Department of Psychiatry, Seoul Medical Center, Seoul, Korea.
- 9Department of Psychiatry, Seoul National Hospital, Seoul, Korea.
- 10Department of Psychiatry, Seoul Eunpyeong Hospital, Seoul, Korea.
- 11Department of Psychiatry, Chosun University College of Medicine, Chosun University Hospital, Gwangju, Korea.
- 12Department of Psychiatry, Naju National Hospital, Naju, Korea.
- 13Department of Psychiatry, Soonchunhyang University College of Medicine, Bucheon Hospital, Bucheon, Korea.
- 14Department of Psychiatry, Korea University College of Medicine, Guro Hospital, Seoul, Korea.
- 15Department of Psychiatry, Yong-In Mental Hospital, Yongin, Korea.
- 16Department of Psychiatry, Inje University College of Medicine, Sanggye Paik Hospital, Seoul, Korea.
- 17SAL Sell Pharm Neuroscience BU head, Janssen Korea, Seoul, Korea.
- 18Inje University College of Medicine, Paik Institute for Clinical Research, Busan, Korea.
- 19FIRST Research Group, Inje University, Busan, Korea.
Abstract
OBJECTIVE
The aim of this study was to demonstrate changes of subjective medication satisfaction and clinical benefit after once-daily paliperidone extended release (ER) in treatment of schizophrenia.
METHODS
In an open-label, observational, and multicenter study, 374 patients with schizophrenia who switched to paliperidone ER due to any reason were recruited. Medication Satisfaction Questionnaire (MSQ), Clinical Global Impression-Severity (CGI-S), Clinical Global Impression-Improvement and visual analogue scale for sleep (VAS) were assessed at baseline, 4 weeks and 8 weeks after treatment. We also examined the type, frequency, and severity of adverse events newly formed.
RESULTS
Among 374 patients, 320 patients (76.5%) were included in the intent-to-treat analysis set. The mean dose of paliperidone ER was 5.33+/-2.31 mg/day at the initiation. At the endpoint, the mean dose of paliperidone ER was 6.68+/-3.13 mg/day. The percentages of patients satisfied with medication were changed from 40.9% at baseline to 67.8% at endpoint (p<0.001). Both CGI-S scores and VAS for daytime drowsiness were significantly decreased after 8 weeks (both p<0.0001) and mean scores of MSQ and VAS for sleep quality were improved after 8 weeks (both p<0.0001).
CONCLUSION
After switching to paliperidone ER, 67.8% of patients with schizophrenia who had any reason to switch medication showed subjective satisfaction for medication and clinical improvement without significant adverse events. Regarding that medication satisfaction was associated with changes of clinical states, medication satisfaction can be used for measures for clinical scales in the treatment of schizophrenia.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
- The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release
- Efficacy and Safety of Paliperidone Extended Release in Schizophrenia Patients Requiring a Switch in Antipsychotic Medication by Switching Previous Antipsychotics to Paliperidone Extended Release
- The Drug Adherence and Treatment Effect of the Paliperidone Long Acting Injection
- A Case of Ileus in a Patient with Schizophrenia Under Paliperidone Palmitate Treatment
